Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - nateglinide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - nateglinide huwa indikat għal terapija kombinata b'metformin f'pazjenti dijabetiċi tat-tip-2 li mhumiex ikkontrollati b'mod adegwat minkejja doża massima ta 'metformin ittollerata waħedha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm ltd. - nateglinide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - nateglinide huwa indikat għal terapija kombinata b'metformin f'pazjenti dijabetiċi tat-tip 2 li mhumiex ikkontrollati b'mod adegwat minkejja doża massima ta 'metformin ittollerata waħedha.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - lixisenatide - diabetes mellitus, tip 2 - drugs used in diabetes, glucagon-like peptide-1 (glp-1) analogues - lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novo nordisk a/s - l-insulina degludec, liraglutide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - xultophy huwa indikat għall-kura ta ' l-adulti ma tip-2 diabetes mellitus biex jitjieb il-kontroll ta ' glycaemic flimkien ma ' l-orali li jitbaxxew il-glukosju prodotti mediċinali meta dawn waħedhom jew kombinati ma ' tal-glp-1 riċevitur agonist jew ta ' insulina bażali ma jipprovdux kontroll adegwat ta ' glycaemic.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - exenatide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - bydureon huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 sabiex ittejjeb il-kontroll gliċemiku f'kombinazzjoni mal oħra li jbaxxu glucose-prodotti mediċinali meta l-terapija fl-użu, flimkien ma' dieta u eżerċizzju, ma jipprovdux kontroll gliċemiku adegwat (ara sezzjoni 4. 4, 4. 5 u 5. 1 għad-data disponibbli dwar kombinazzjonijiet differenti). bydureon huwa indikat għat-trattament tad-dijabete mellitus tip 2 flimkien ma': metforminsulphonylureathiazolidinedionemetformin u sulphonylureametformin u thiazolidinedionein-adulti li ma kisbux kontroll gliċemiku adegwat fuq massima tollerata-dożi ta ' dawn it-terapiji orali.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanedjol monohydrate, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - dijabete tat-tip 2 mellitusfor-trattament ta mhumiex ikkontrollati biżżejjed b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju. bħala monoterapija meta metformin huwa meqjus bħala mhux xierqa minħabba l-intolleranza. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. għall-riżultati tal-istudju fir-rigward tal-kombinazzjoni ta ' terapiji, l-effetti fuq il-kontroll gliċemiku u episodji kardjovaskulari, u l-popolazzjonijiet studjati, ara sezzjonijiet 4. 4, 4. 5 u 5. dijabete tat-tip 1 mellitusedistride huwa indikat fl-adulti għall-kura ta mhumiex ikkontrollati biżżejjed dijabete mellitus tip 1 bħala kura aġġuntiva għall-insulina f'pazjenti b'bmi ≥ 27 kg/m2, meta l-insulina waħdu ma jipprovdux kontroll gliċemiku adegwat minkejja l-aħjar terapija ta'l-insulina.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - repaglinide - diabetes mellitus, tip 2 - drogi użati fid-dijabete - repaglinide huwa indikat fil-pazjenti bl-dijabete tat-tip-2 (mhux-insulina - dipendenti diabetes mellitus (niddm)) tagħhom hyperglycaemia jistgħu aktar jiġu kkontrollati b'mod sodisfaċenti minn dieta, piż tnaqqis u l-eżerċizzju. repaglinide huwa indikat ukoll flimkien ma 'metformin f'pazjenti bid-dijabete tat-tip-2 li mhumiex ikkontrollati b'mod sodisfaċenti fuq metformin waħdu. il-kura għandha tinbeda bħala żieda mad-dieta u l-eżerċizzju biex ibaxxi l-glucose fid-demm fir-rigward ta'l-ikel.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - empagliflozin, linagliptin - diabetes mellitus, tip 2 - drogi użati fid-dijabete - glyxambi, taħlita fissa tad-doża ta empagliflozin u linagliptin, huwa indikat f'adulti ta ' 18-il sena u akbar b'dijabete mellitus tip 2:biex ittejjeb il-kontroll gliċemiku meta metformin u/jew mediċina tat-tip sulphonylurea (su) u waħda mill-monokomponenti tal-glyxambi ma jipprovdux kontroll gliċemiku adegwat;meta diġà qegħdin jiġu ttrattati bil-kombinazzjoni ħielsa ta empagliflozin u linagliptin.